Literature DB >> 27222138

New Directions in Medication-Facilitated Behavioral Treatment for Substance Use Disorders.

Elias Dakwar1, Edward V Nunes2.   

Abstract

A promising approach to addressing substance use disorders is to integrate pharmacotherapy with a behavioral treatment with which synergy is possible. In this review, we focus on recent research suggesting that this approach may be effective for cocaine and cannabis use disorders, both of which currently lack efficacious medications. We summarize potential targets of pharmacotherapy of particular relevance to combined medication-behavioral treatment and examine preliminary evidence of clinical efficacy. Common to these promising medications is a hypothesized mechanism of action predicated on reversing drug-related neural adaptations, such as high reactivity to stress or drug cues, that might undermine fruitful engagement with behavioral treatment. We also review emerging medications, such as certain glutamatergic and serotonergic agents, which may be feasibly integrated with existing treatments. We conclude with an outline of future directions for research.

Keywords:  Addiction; Behavioral treatment; Cannabis; Cocaine; Combined treatment; Medication; Use disorder

Mesh:

Substances:

Year:  2016        PMID: 27222138     DOI: 10.1007/s11920-016-0703-4

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  76 in total

Review 1.  New insights into the mechanism of action of amphetamines.

Authors:  Annette E Fleckenstein; Trent J Volz; Evan L Riddle; James W Gibb; Glen R Hanson
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

Review 2.  Understanding and preventing relapse.

Authors:  K D Brownell; G A Marlatt; E Lichtenstein; G T Wilson
Journal:  Am Psychol       Date:  1986-07

3.  Postcocaine anhedonia. An animal model of cocaine withdrawal.

Authors:  A Markou; G F Koob
Journal:  Neuropsychopharmacology       Date:  1991-01       Impact factor: 7.853

4.  Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.

Authors:  B Moghaddam; B Adams; A Verma; D Daly
Journal:  J Neurosci       Date:  1997-04-15       Impact factor: 6.167

5.  Correlation of glutamate levels in the anterior cingulate cortex with self-reported impulsivity in patients with borderline personality disorder and healthy controls.

Authors:  Mareen Hoerst; Wolfgang Weber-Fahr; Nuran Tunc-Skarka; Matthias Ruf; Martin Bohus; Christian Schmahl; Gabriele Ende
Journal:  Arch Gen Psychiatry       Date:  2010-07-05

6.  Influence of outpatient treatment and 12-step group involvement on one-year substance abuse treatment outcomes.

Authors:  P C Ouimette; R H Moos; J W Finney
Journal:  J Stud Alcohol       Date:  1998-09

Review 7.  Glutamatergic substrates of drug addiction and alcoholism.

Authors:  Justin T Gass; M Foster Olive
Journal:  Biochem Pharmacol       Date:  2007-06-30       Impact factor: 5.858

8.  An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

Authors:  Sheldon H Preskorn; Bryan Baker; Sheela Kolluri; Frank S Menniti; Michael Krams; Jaren W Landen
Journal:  J Clin Psychopharmacol       Date:  2008-12       Impact factor: 3.153

9.  Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

Authors:  Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2007-07-23       Impact factor: 13.382

10.  Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action.

Authors:  Milan Scheidegger; Martin Walter; Mick Lehmann; Coraline Metzger; Simone Grimm; Heinz Boeker; Peter Boesiger; Anke Henning; Erich Seifritz
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

View more
  2 in total

1.  Targeting white matter neuroprotection as a relapse prevention strategy for treatment of cocaine use disorder: Design of a mechanism-focused randomized clinical trial.

Authors:  Joy M Schmitz; Scott D Lane; Michael F Weaver; Ponnada A Narayana; Khader M Hasan; DeLisa D Russell; Robert Suchting; Charles E Green
Journal:  Contemp Clin Trials       Date:  2021-10-22       Impact factor: 2.226

2.  Toward Synergies of Ketamine and Psychotherapy.

Authors:  David S Mathai; Victoria Mora; Albert Garcia-Romeu
Journal:  Front Psychol       Date:  2022-03-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.